Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Jemal A et al. Cancer statistics, 2018. CA Cancer J. Clin. 68(1), 7–30 (2018).
  MedlineGoogle Scholar
• 2. Colombo PE, Fabbro M, Theillet C et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit. Rev. Oncol. Hematol. 89(2), 207–216 (2014).
  MedlineGoogle Scholar
• 3. Seidman JD, Horkayne-Szakaly I, Haiba M et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23(1), 41–44 (2004).
  MedlineGoogle Scholar
• 4. Basu M, Mukhopadhyay S, Chatterjee U et al. FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J. Biol. Chem. 289(3), 1415–1428 (2014).
  Medline CASGoogle Scholar
• 5. Perkel JM. Visiting “noncodarnia”. Biotechniques 54(6), 301–304 (2013).
  Medline CASGoogle Scholar
• 6. Bu D, Yu K, Sun S et al. NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res. 40(Database issue), D210–D215 (2012).
  Medline CASGoogle Scholar
• 7. Amaral PP, Clark MB, Gascoigne DK et al. lncRNAdb: a reference database for long noncoding RNAs. Nucleic Acids Res. 39(Database issue), D146–D151 (2011).
  Medline CASGoogle Scholar
• 8. Quek XC, Thomson DW, Maag JL et al. lncRNAdb v2.0: expanding the reference database for functional long noncoding RNAs. Nucleic Acids Res. 43(Database issue), D168–D173 (2015).
  Medline CASGoogle Scholar
• 9. Prensner JR, Iyer MK, Sahu A et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45(11), 1392–1398 (2013).
  Medline CASGoogle Scholar
• 10. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071–1076 (2010).
  Medline CASGoogle Scholar
• 11. Fan Y, Shen B, Tan M et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J. 281(7), 1750–1758 (2014).
  Medline CASGoogle Scholar
• 12. Liu R, Zeng Y, Zhou CF et al. Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci. Rep. 7(1), 18 (2017).
  MedlineGoogle Scholar
• 13. LINC00515 long intergenic non-protein coding RNA 515 [Homo sapiens (human)]. Gene ID: 282566 (2018). www.ncbi.nlm.nih.gov/gene/282566
  Google Scholar
• 14. Zheng ZG, Xu H, Suo SS et al. The essential role of H19 contributing to cisplatin resistance by regulating glutathione metabolism in high-grade serous ovarian cancer. Sci. Rep. 6, 26093 (2016).•• First report on the downregulation of LINC00515 in cisplatin-resistant A2780-DR cells.
  Medline CASGoogle Scholar
• 15. Vajpeyi R. WHO classification of tumours: pathology and genetics of tumours of the breast and female genital organs. J. Clin. Pathol. 58(6), 671–672 (2005).
  MedlineGoogle Scholar
• 16. Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch. Gynecol. Obstet. 290(5), 839–842 (2014).
  Medline CASGoogle Scholar
• 17. Fung-Kee-Fung M, Oliver T, Elit L et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr. Oncol. 14(5), 195–208 (2007).
  Medline CASGoogle Scholar
• 18. Du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320–1329 (2003).
  MedlineGoogle Scholar
• 19. Tian Z, Wen S, Zhang Y et al. Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma. Oncotarget 8(31), 51703–51718 (2017). • Possible mechanism of LINC00515 participates in the development of drug resistance.
  MedlineGoogle Scholar
• 20. Wang Y, Lieberman R, Pan J et al. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol. Cancer. 15(1), 70 (2016).
  MedlineGoogle Scholar
• 21. Mussnich P, Rosa R, Bianco R et al. MiR-199a-5p and miR-375 affect colon cancer cell sensitivity to cetuximab by targeting PHLPP1. Expert Opin. Ther. Targets 19(8), 1017–1026 (2015).
  Medline CASGoogle Scholar
• 22. Zhang M, Liu T, Xia B et al. Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer. Int. J. Gynecol. Cancer 28(2), 323–331 (2018).
  Medline CASGoogle Scholar
• 23. Zhang D, Gao J, Zhu L et al. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. Int. J. Mol. Sci. 14(6), 11024–11033 (2013).
  MedlineGoogle Scholar
• 24. Polterauer S, Vergote I, Concin N et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA–IV: analysis of the OVCAD data. Int. J. Gynecol. Cancer 22(3), 380–385 (2012).
  MedlineGoogle Scholar
• 25. Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol. Oncol. 108(2), 276–281 (2008).
  Medline CASGoogle Scholar
• 26. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res. 72(11), 2701–2704 (2012).
  Medline CASGoogle Scholar